Find more about what it takes for hepatocytes to be Transporter Certified^TM

• A Service Project that answers the question "Does my compound demonstrate the potential for clinically significant hepatic transporter interactions?"
• Compounds are often substrates or inhibitors of multiple transporters, and an integrated system with multiple transporters, expressed, localized and functioning similar to in vivo is critical to successfully predict the clinical outcome.
• Using B-CLEAR^® Transporter Certified^TM hepatocytes we evaluate the potential for hepatic transporter interactions (NTCP, OATP, BSEP, P-GP, MRP2, and BCRP) using an FDA accepted system and clinically-relevant probe substrates and inhibitors, including positive controls.
• Click here to view our FDA Services Press Release

• A kit or service project that can assess the time and dose-dependent accumulation of your compound and estimate the intracellular concentration.
• Transporter Certified^TM hepatocytes, using the B-CLEAR^® technology, are the best way to determine the intracellular concentration of your compound and has been cited by the FDA as the model of choice. [Nature Reviews]
• Results from Hepatic Exposure studies provide a more relevant exposure and concentration estimate compared to plasma levels because the intracellular concentration better reflects compound at the target or site of action.

• A kit or service-based solution to rapidly assess hepatobiliary disposition (hepatic uptake, biliary excretion, intracellular concentration and in vitro biliary clearance) and identify potential transporter-based interactions for your compound.
• Using Transporter Certified^TM hepatocytes ensures functionally active uptake and efflux transporter proteins providing an integrated transport system that is proven to be predictive of in vivo outcomes.
• Data allows for the categorization of compounds based on biliary excretion, in vitro biliary clearance and can determine potential transporter-based drug interactions.

• Kits containing Transporter Certified^TM hepatocytes used to evaluate the hepatotoxicity of your compound. Hepatocytes from multiple species are available.
• Transporter Certified^TM hepatocytes demonstrate in vivo relevant transporter function, generating clinically relevant intracellular concentrations to optimize toxicity prediction.
• Each kit comes with certification data, reagents, and protocols to make it easy to use in toxicology studies.

• A research service offering to assess your compounds potential to alter the profile of bile acids in the hepatocyte as well as the basolateral (blood) or canalicular (bile) efflux of bile acids.
• This offering is the only in vitro system that uses endogenously generated bile acids, which means in vivo relevance, to access basolateral or canalicular transporter interactions, as well as, bile acid metabolism.
• B-CLEAR^® Transporter Certified^TM hepatocytes, from multiple species, are quantitatively profiled, utilizing stable isotope-based LC/MS/MS, for bile acids following treatment with vehicle control and your compound. Quantitative information can be related to in vivo effects of your compound.

• A research service offering that provides accurate and sensitive measurements of your compound’s effect on bilirubin and its mono- and di-glucuronides in the hepatocyte.
• In vitro data that predicts the in vivo effects of your compound on the disposition of bilirubin, including changes in blood levels and liver concentrations. This can also be used to evaluate species differences and for species selection.
• Combining the B-CLEAR^® technology and Transporter Certified^TM hepatocytes with sensitive LC/MS analysis, we supply in vivo -relevant data on your compound’s potential to alter the hepatobiliary disposition (uptake, efflux, and metabolism) of bilirubin and its metabolites.